FRESENIUS KABI USA LLC lobbying for FRESENIUS KABI USA LLC

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$630,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Illinois

Official filing document

Government bodies contacted 9

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Medicare/Medicaid

S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) Domestic Manufacturing of Essential Medicines

Copyright/Patent/Trademark

S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) PTAB: Proposed Rule, Settled Expectations, Patent Thickets and Ancillary Product Patents, Discretionary Denials

Health Issues

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act H.R. 10369: Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 S. 2658: Medication Affordability and Patent Integrity Act (MAPIA) S. 1954/H.R. 5526: Biosimilar Red Tape Elimination Act (BRTEA) S. 1414: Expedited Access to Biosimilars Act S. 43/H.R. 26485: Skinny Labels, Big Savings Act S. 3549/H.R. 6837: PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act Toxic-Free Medical Devices Drug Enforcement Administration Quotas Department of Labor Proposed and Final PBM Transparency Rule 340b Contract Pharmacies

Manufacturing

Domestic Manufacturing of Essential Medicines

Bills named in this filing 11

S. 2658
Medication Affordability and Patent Integrity Act
S. 2276
ETHIC Act
H.R. 3269
ETHIC Act
H.R. 10369
Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026
S. 1954
Biosimilar Red Tape Elimination Act
H.R. 5526
Biosimilar Red Tape Elimination Act
S. 1414
Expedited Access to Biosimilars Act
S. 43
Skinny Labels, Big Savings Act
119-HR-26485
Not yet in our database
S. 3549
PBM FAIR Act
H.R. 6837
To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fi…